Understanding Cyclophotocoagulation: Procedure, Risks, and Recovery

Posted by: Northwest Eye in Innovative Ophthalmic Technology on July 18, 2026

Introduction

We know that understanding eye health can feel overwhelming at times, especially with conditions like glaucoma. Cyclophotocoagulation offers hope for many patients dealing with elevated intraocular pressure. This laser-based solution targets the ciliary body to reduce fluid production, but it’s common to have questions about its effectiveness, risks, and recovery process.

What can you do to prepare for this treatment journey, and how can we help you achieve the best possible outcomes?

Define Cyclophotocoagulation and Its Mechanism

If you’re feeling overwhelmed by elevated eye pressure, know that there are effective options available, including the treatment known as cyclophotocoagulation. This technique uses a laser to carefully target parts of the ciliary body. By doing so, it reduces the production of aqueous humor, which helps lower intraocular pressure (IOP). This decrease in fluid production is essential for controlling eye pressure, especially for those who haven’t found relief with other treatments. The laser energy is delivered in a controlled manner, ensuring minimal damage to surrounding tissues while effectively addressing the underlying issue of elevated eye pressure.

Many patients have experienced significant IOP reductions with cyclophotocoagulation, considering it a turning point in their treatment journey. For instance, one study reported a mean IOP decrease from 39.1 mmHg preoperatively to 18.5 mmHg at two years post-treatment, representing a 42.9% reduction. Moreover, the success rate for CPC procedures has been observed to reach as high as 62%, although this rate can vary based on individual circumstances, particularly in cases of neovascular conditions, which may require more frequent treatments.

In the Midwest, especially within the Twin Cities, cyclophotocoagulation (CPC) has gained traction as an effective treatment option for individuals with refractory glaucoma. While we understand that complications like hypotony and phthisis bulbi can be concerning, many patients navigate these challenges successfully. As our understanding of cyclophotocoagulation continues to evolve, ongoing research aims to establish optimal energy levels and treatment parameters to enhance outcomes for individuals suffering from this challenging condition. With ongoing advancements in treatment, many patients are finding renewed hope and relief from their symptoms.

Identify Candidates for Cyclophotocoagulation

We understand that dealing with resistant eye conditions can be challenging and emotionally taxing. Many individuals facing these conditions often feel frustrated when standard treatments, like medications or previous surgeries, don’t provide the relief they seek. For those who have faced setbacks with trabeculectomy or tube shunt surgeries, cyclophotocoagulation (CPC) may offer a suitable option and a new avenue for hope. Additionally, if you have advanced eye disease, limited visual potential, or are unable to undergo incisional surgery, CPC might be an option worth discussing with your doctor.

In Minnesota, we see that many older adults, especially those aged 60 and above, are facing these challenging eye conditions, which can be particularly concerning. It’s important to have a thorough assessment by your ophthalmologist to understand if the benefits of cyclophotocoagulation are greater than the risks for you.

Stories from the Twin Cities show how cyclophotocoagulation (CPC) has assisted many patients with advanced eye conditions in finding relief when other treatments fell short. These experiences remind us how vital personalized evaluations are in finding the right treatment for those facing complex eye challenges. With the right support and treatment, you can find a path toward better eye health.

Explain the Cyclophotocoagulation Procedure Steps

We understand that facing a procedure like cyclophotocoagulation can be daunting, but being informed about what to expect can help ease your concerns. Here’s a look at what typically happens during the procedure:

1. Preoperative Assessment: Your ophthalmologist will take the time to perform a thorough eye examination to ensure you’re a good candidate for the procedure, helping you feel confident in your care. It’s important to bring a list of your current medications and a brief medical history, especially if you’re taking blood thinners like Coumadin. Remember, you should continue using any prescribed eye drops until your doctor advises otherwise.
2. Local numbing agents are applied to desensitize your eye, ensuring you feel as comfortable as possible during the process. We know that it’s common to feel anxious about this step, but it’s designed to minimize discomfort during the laser application.
3. Laser Application: A specialized laser probe is gently placed on the sclera (the white part of your eye). Your surgeon will direct laser energy towards the ciliary body, delivering controlled pulses that selectively target the tissue. This process aims to reduce aqueous humor secretion, helping to lower intraocular pressure (IOP).
4. Monitoring: Throughout the procedure, your vital signs and eye response will be closely observed to ensure your safety and the effectiveness of the treatment. This real-time evaluation allows for any necessary adjustments, keeping your comfort in mind.
5. Postoperative Care: After your procedure, we’ll provide you with atropine 1% eye drops to help with your recovery, ensuring you have the support you need during this time. Follow-up appointments will be scheduled to monitor your recovery and assess how well the treatment is working. Effective postoperative management is essential for minimizing complications and ensuring optimal IOP control, enhancing your overall treatment outcomes.

In terms of comfort, studies have shown that both micropulse transscleral cyclophotocoagulation (MP-TSCPC) and slow-coagulation continuous-wave transscleral cyclophotocoagulation (SC-TSCPC) utilize cyclophotocoagulation techniques that have favorable safety profiles, with minimal complications reported. For example, the average intraocular pressure reduction noted in individuals undergoing these procedures was 11.20 ± 11.46 mmHg for MP-TSCPC and 19.65 ± 13.22 mmHg for SC-TSCPC at 12 months. Additionally, 70.21% of individuals in the micropulse group achieved IOP control without eye drops at the end of treatment, compared to 29.79% in the slow cook group. The average energy utilized was 213.22 ± 45.01 J in the micropulse group and 143.94 ± 30.22 J in the slow cook group, emphasizing the procedural differences and their implications for outcomes. With proper care and follow-up, many patients find renewed hope and relief from their glaucoma symptoms, allowing them to enjoy life more fully.

Discuss Risks and Complications of Cyclophotocoagulation

We understand that considering cyclophotocoagulation can bring up many questions and concerns about your eye health, and it’s important to be aware of potential risks and complications:

• Intraocular Pressure Fluctuations: It’s common to experience postoperative spikes in intraocular pressure (IOP). Studies show that nearly 40% of eyes may have an IOP spike within the first 24 hours. This fluctuation can affect surgical results and visual function, especially for those with compromised optic disks. In fact, significant IOP spikes were noted in 11.5% of eyes just one hour after the procedure.
• Inflammation: Postoperative inflammation can lead to discomfort and blurred vision. While this can be managed with appropriate medications, it’s essential to be aware that this possibility exists.
• Vision Loss: Although rare, there is a risk of permanent vision impairment, particularly for individuals with advanced eye conditions. While the occurrence of notable vision loss is low, it remains a significant consideration for those undergoing treatment.
• Hypotony: This condition, characterized by abnormally low IOP, can occur after treatment and may require further intervention. Studies have shown that hypotony was observed in 17.6% of eyes, particularly among individuals with neovascular issues, highlighting the importance of monitoring IOP levels after surgery.

It’s natural to feel concerned about the risks associated with your treatment. Some patients may need further treatments if the initial care does not sufficiently manage their glaucoma. The overall retreatment rate for cyclophotocoagulation using diode laser (DCPC) has been reported at 38.9%, indicating that staying in touch with your ophthalmologist is crucial for your ongoing care.

We encourage you to talk openly with your ophthalmologist about these risks. This way, you can feel more empowered and prepared for your treatment journey.

Outline Recovery and Aftercare Following Cyclophotocoagulation

We understand that the recovery process after undergoing cyclophotocoagulation can bring about a mix of emotions and questions. To help you navigate this journey, here are several key steps to ensure optimal healing and management of intraocular pressure (IOP):

1. Immediate Postoperative Care: We know that you may feel anxious after the procedure, so we closely monitor you during this time to ensure everything is going smoothly.
2. Eye Drops: Your doctor will prescribe anti-inflammatory and antibiotic eye drops to help mitigate the risk of infection and manage inflammation effectively.
3. Activity Restrictions: It’s common to feel uncertain about what you can do after surgery. To prevent complications, please refrain from strenuous activities, heavy lifting, and swimming for at least one week post-surgery.
4. Follow-Up Appointments: We encourage you to attend your follow-up visits, as they play a vital role in ensuring your healing process is on track. If you notice any unusual symptoms, such as increased pain or changes in vision, please reach out to your ophthalmologist right away.
5. Long-Term Monitoring: Continuous monitoring of eye pressure and overall eye health is crucial, as glaucoma is a chronic condition requiring ongoing management.

Statistics indicate that the mean time to failure for the first and second continuous-wave transscleral cyclophotocoagulation treatments is approximately 79.5 and 77.1 days, respectively, highlighting the effectiveness of cyclophotocoagulation. Enrico Bernardi noted, “The mean time to failure was 79.5 ± 24.6 and 77.1 ± 29.4, respectively.” A significant reduction in IOP is observed, with a 45.6% decrease noted three months after the second treatment. Bernardi stated, “At 3 months follow-up of the first cyclophotocoagulation treatment, a 24.8% decrease in IOP was observed, whereas a 45.6% decrease in IOP was noted 3 months after the second cyclophotocoagulation treatment.” Importantly, visual acuity remains stable, and no major complications have been reported during follow-up periods, as highlighted by Bernardi: “Visual acuity did not decrease, and no major complications were observed post either treatment within the follow-up period.”

Here in Minnesota, we’re committed to providing you with a supportive recovery environment, where our healthcare providers will guide you every step of the way to ensure you feel confident in your aftercare. With the right support and guidance, you can navigate this journey with confidence and peace of mind.

Conclusion

We know that understanding cyclophotocoagulation can feel daunting, especially when dealing with elevated intraocular pressure and the search for effective treatment options. This procedure is designed to help manage glaucoma by focusing on reducing the fluid in your eye, which can lead to lower pressure and better comfort. We understand that making decisions about your eye health can feel overwhelming, but knowing the details can help you feel more in control.

It’s important to stay in touch with your ophthalmologist about any risks or concerns you might have, as they can guide you through this process. The recovery process is also outlined, providing you with a clear understanding of what to expect and how to ensure optimal healing.

For many, cyclophotocoagulation can be a hopeful option, especially if traditional treatments haven’t provided the relief you need. By embracing this proactive approach, you can take charge of your eye health and feel empowered in your treatment journey.

Frequently Asked Questions

What is cyclophotocoagulation and how does it work?

Cyclophotocoagulation is a laser treatment that targets parts of the ciliary body to reduce the production of aqueous humor, thereby lowering intraocular pressure (IOP). This technique is particularly beneficial for patients who have not found relief with other treatments.

What are the expected outcomes of cyclophotocoagulation?

Many patients experience significant reductions in IOP after cyclophotocoagulation. For example, one study reported a mean IOP decrease from 39.1 mmHg preoperatively to 18.5 mmHg at two years post-treatment, representing a 42.9% reduction. The success rate for CPC procedures can reach up to 62%, although this may vary based on individual circumstances.

Who are the ideal candidates for cyclophotocoagulation?

Ideal candidates for cyclophotocoagulation include individuals who have faced setbacks with standard treatments like trabeculectomy or tube shunt surgeries, those with advanced eye disease, limited visual potential, or those unable to undergo incisional surgery. A thorough assessment by an ophthalmologist is essential to determine if the benefits outweigh the risks.

What demographic is particularly affected by conditions that may require cyclophotocoagulation?

In Minnesota, many older adults, especially those aged 60 and above, are facing challenging eye conditions that may necessitate treatments like cyclophotocoagulation.

What are some potential complications associated with cyclophotocoagulation?

Potential complications from cyclophotocoagulation include hypotony and phthisis bulbi. However, many patients successfully navigate these challenges with proper care and support.

How is cyclophotocoagulation viewed in the Twin Cities?

Cyclophotocoagulation has gained traction in the Twin Cities as an effective treatment option for individuals with refractory glaucoma, providing renewed hope and relief for many patients facing complex eye challenges.

List of Sources

1. Define Cyclophotocoagulation and Its Mechanism
   • Efficacy and Safety of Diode Laser Transscleral Cyclophotocoagulation in Patients with Glaucoma – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC11330864)
   • Success of Endoscopic Laser Cyclophotocoagulation vs Repeat Transscleral Treatment after Prior Transscleral Cycloablation – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC10803276)
   • Long‐term outcome of trans‐scleral diode laser cyclophotocoagulation in refractory glaucoma – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC2095557)
2. Identify Candidates for Cyclophotocoagulation
   • Facts & Figures – Glaucoma (https://brightfocus.org/glaucoma/facts-figures)
   • VEHSS Modeled Estimates: Prevalence of Glaucoma (https://cdc.gov/vision-health-data/prevalence-estimates/prevalence-estimates-glaucoma.html)
   • Refractory Glaucoma Treatment Market Size By 2028 (https://coherentmarketinsights.com/market-insight/refractory-glaucoma-treatment-market-71)
   • Updated Prevalence of Glaucoma in the United States (https://aao.org/eyenet/article/updated-prevalence-glaucoma-united-states)
3. Explain the Cyclophotocoagulation Procedure Steps
   • Cyclodestructive Procedures in Treatment of Glaucoma – EyeWiki (https://eyewiki.org/Cyclodestructive_Procedures_in_Treatment_of_Glaucoma)
   • Transscleral vs endoscopic cyclophotocoagulation: safety and efficacy when combined with phacoemulsification – BMC Ophthalmology (https://link.springer.com/article/10.1186/s12886-023-02877-6)
   • Comparison of safety and effectiveness of micropulse transscleral cyclophotocoagulation and “slow cook” diode laser transscleral cyclophotocoagulation in patients with refractory open-angle glaucoma (https://scielo.br/j/abo/a/LKrZbSKd3JFVqxHCqNfgkTt?lang=en)
   • Comparison of Efficacy and Safety of Slow Coagulation Transscleral versus Micropulse Cyclophotocoagulation in Refractory Glaucoma (https://openophthalmologyjournal.com/VOLUME/18/ELOCATOR/e18743641310116/FULLTEXT)
4. Discuss Risks and Complications of Cyclophotocoagulation
   • Changes in intraocular pressure during the first 24 h after transscleral cyclophotocoagulation (https://onlinelibrary.wiley.com/doi/full/10.1111/aos.16652)
   • Changes in intraocular pressure during the first 24 h after transscleral cyclophotocoagulation (https://opinvisindi.is/items/12002f03-82bd-4300-a56a-8993a989f9c2)
   • Early Postoperative Intraocular Pressure Profile Following Micropulse vs Continuous Wave Transscleral Cyclophotocoagulation: Cohort Study – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC12096860)
   • Long‐term outcome of trans‐scleral diode laser cyclophotocoagulation in refractory glaucoma – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC2095557)
5. Outline Recovery and Aftercare Following Cyclophotocoagulation
   • First and second transscleral cyclophotocoagulation treatments provide similar intraocular pressure-lowering efficacy in patients with refractory glaucoma – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC9314293)
   • Treatment outcomes of slow-coagulation transscleral cyclophotocoagulation for refractory glaucoma (https://researchgate.net/publication/404467594_Treatment_outcomes_of_slow-coagulation_transscleral_cyclophotocoagulation_for_refractory_glaucoma)
   • Treatment Outcomes of Slow Coagulation Transscleral Cyclophotocoagulation In Pseudophakic Patients with Medically Uncontrolled Glaucoma – PubMed (https://pubmed.ncbi.nlm.nih.gov/33852906)